A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01749423|
Recruitment Status : Withdrawn (Company decision due to enrollment challenges.)
First Posted : December 13, 2012
Last Update Posted : February 3, 2014
|Condition or disease||Intervention/treatment|
|Chronic Migraine, Headache||Biological: OnabotulinumtoxinA|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Study Start Date :||November 2012|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
Previous treatment with onabotulinumtoxinA for Chronic Migraine.
- Number of Headache Days [ Time Frame: Up to 56 Weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01749423
|Study Director:||Medical Director||Allergan|